Table 3

Comparison of test assay titers in patients with versus those without a distinct present clinical findinga

P value

Disease feature

Number of patients

NcX

dsDNA

Nuc

Farr

CLIF


ACR criteria (ever), N = 207

Renal

101

0.01

0.03

0.01

ns

ns

Neurologic

23

0.01

0.03

0.01

0.04

ns

Hematological

134

ns

ns

ns

ns

0.04

mSLEDAI 2000 (current), N = 165

Casts

3

0.03

0.04

0.04

0.02

0.04

Hematuria

13

<0.001

0.001

0.003

0.002

ns

Proteinuria

16

0.04

ns

ns

ns

ns

Leukocyturia

3

0.04

0.02

ns

ns

ns

Pleuritis

5

ns

ns

ns

0.01

ns

Pericarditis

10

ns

0.02

ns

ns

ns

Complement

84

0.003

0.005

0.004

0.01

0.03

Fever

8

0.02

0.04

ns

ns

ns

Thrombocytes

5

ns

0.04

ns

ns

0.03

Laboratory (current), N = 165

Decreased lymphocytes

91

0.02

0.02

ns

0.03

ns

Decreased monocytes

27

0.02

0.02

ns

ns

ns

Decreased C-reactive protein

62

0.02

0.04

0.04

ns

ns

Decreased C3

83

0.004

0.001

0.01

0.004

ns

Decreased C4

63

ns

0.04

ns

ns

ns

Proteinuria >150 mg/d

39

0.01

ns

0.04

ns

ns


aComparison was performed using the Mann-Whitney U test. This table is reduced to statistically significant findings to increase readability. Significance with regard to any feature was always found for increased values of autoantibody assays. The number of patients with a positive finding (ACR and SLEDAI 2000) or an abnormal finding (local laboratory) of all patients is given. Current values refer to values on the date of blood withdrawal. NcX, anti-dsDNA-nucleosome-complexed enzyme-linked immunosorbent assay (ELISA); dsDNA, dsDNA, double-stranded DNA; Nuc, anti-dsDNA-nucleosome ELISA; Farr, radioimmunoassay; CLIF, Crithidia luciliae immunofluorescence assay; ACR, American College of Rheumatology; mSLEDAI 2000, modified Systemic Lupus Erythematosus Disease Activity Index 2000 [25]; C3, complement component C3; C4, complement component C4; ns, not significant.

Biesen et al. Arthritis Research & Therapy 2011 13:R26   doi:10.1186/ar3250

Open Data